Establishment of a cervical cancer bio-bank for the Chinese population: from project-based sample collection to routine management

Yang, Ru; Li, Xiong; Zhou, Huaqiang; Jia, Yulin; Zhou, Jin; Huang, Kecheng; Tang, Fangxu; Hu, Ting; Shen, Jian; Chen, Zhilan; Wang, Shaoshuai; Sun, Haiying; Guo, Lili; Wang, Lin; Wang, Hui; Ma, Ding; Li, Shuang

doi:10.1007/s00404-015-3622-4

Cited by 1 publication

(1 citation statement)

References 14 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the development of a hierarchical medical system in China, coagulation tests, FVIII:C, and FIX:C in some samples cannot be detected in community hospitals and clinics, and thus the collected samples are sent to independent clinical laboratories for analysis [9][10][11]. Moreover, the establishment of biobanks to facilitate the development of drugs and diagnostic tests has led to the development of biobank networks that collect and preserve large numbers of high-quality clinical biospecimens [12,13]. Although our preliminary tests established the shortterm/long-term storage times and optimal temperatures for screening coagulation tests on FVIII:C and FIX:C freeze-thaw cycles and temperatures are lacking for these items in citrate-anticoagulated plasma samples [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Effects of Freeze-Thaw Times on Screening Coagulation Tests and Factors VIII and IX Activities in Citrate-Anticoagulated Plasma at -20°C and -80°C

Feng¹,

Zhao²,

Zhang³

et al. 2018

Clin. Lab.

View full text Add to dashboard Cite

Background: Accurate determination of screening coagulation tests and factors VIII and IX activities (FVIII:C and FIX:C) in fresh plasma is very important for diagnosing abnormalities in the intrinsic or extrinsic coagulation pathways and factor deficiencies. If thawed samples cannot be detected for all required items at the same time, or need to be re-tested or restored , the thawed samples need to be re-frozen. We planned to perform in-house validation studies on freeze-thawed samples for screening coagulation tests, FVIII:C and FIX:C. Methods: Mean percent changes, numbers of samples with > 10% changes, and difference plots were evaluated to determine clinically relevant differences between results for fresh and freeze-thawed samples. The statistical significance of differences between repeated-measure multiple groups and baseline values were evaluated by repeated-measures analysis of variance. Results: The acceptable freeze-thaw cycles for activated partial thromboplastin time, fibrinogen, prothrombin time/international normalized ratio, thrombin time, and FIX:C were three times at-20°C/-80°C, while the acceptable freeze-thaw cycles for FVIII:C were three times at-80°C and once at-20°C. Conclusions: The freeze-thaw results on stabilities were affected by time and temperature, with lower temperature and fewer times associated with more stable activity.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Freeze-Thaw Times on Screening Coagulation Tests and Factors VIII and IX Activities in Citrate-Anticoagulated Plasma at -20°C and -80°C

Feng¹,

Zhao²,

Zhang³

et al. 2018

Clin. Lab.

View full text Add to dashboard Cite

show abstract

Establishment of a cervical cancer bio-bank for the Chinese population: from project-based sample collection to routine management

Abstract: This bio-bank of cervical cancer specimens from the Chinese population will greatly promote the studies of cervical cancer in China.

Cited by 1 publication

References 14 publications

Effects of Freeze-Thaw Times on Screening Coagulation Tests and Factors VIII and IX Activities in Citrate-Anticoagulated Plasma at -20°C and -80°C

Effects of Freeze-Thaw Times on Screening Coagulation Tests and Factors VIII and IX Activities in Citrate-Anticoagulated Plasma at -20°C and -80°C

Contact Info

Product

Resources

About